Filtered By:
Condition: Heart Failure
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 7255 results found since Jan 2013.

Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis
CONCLUSION: In South African individuals with private health insurance, a perindopril-based antihypertensive regimen provided better clinical and cost outcomes compared with other regimens.PMID:37730949 | DOI:10.1007/s12325-023-02641-8
Source: Adv Data - September 21, 2023 Category: Epidemiology Authors: Jacques R Snyman Freedom Gumedze Erika S W Jones Olufunke A Alaba Nqoba Tsabedze Alykhan Vira Ntobeko A B Ntusi Source Type: research

Association of psoriasis and stroke in end-stage renal disease patients
CONCLUSIONS: Contrary to prior research in the general population, psoriasis in ESRD patients was not associated with the risk of stroke after controlling for various demographic and clinical parameters. Our finding emphasizes the importance of controlling for a variety of factors in population studies examining associations of diseases and risk factors.PMID:37716600 | DOI:10.1016/j.amjms.2023.09.014
Source: The American Journal of the Medical Sciences - September 16, 2023 Category: General Medicine Authors: Naomi Siddiquee Jennifer L Waller Stephanie L Baer Azeem Mohammed Sarah Tran Sandeep Padala Lufei Young Mufaddal Kheda Wendy B Bollag Source Type: research

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Retrospective cohort study investigating synergism of air pollution and corticosteroid exposure in promoting cardiovascular and thromboembolic events in older adults
Conclusion PM2.5 and systemic corticosteroid use were independently associated with increases in CTE hospitalisations. We also found evidence of significant additive interactions between the two exposures for HF and MI/ACSs suggesting synergy between these two exposures.
Source: BMJ Open - September 13, 2023 Category: General Medicine Authors: Josey, K., Nethery, R., Visaria, A., Bates, B., Gandhi, P., Parthasarathi, A., Rua, M., Robinson, D., Setoguchi, S. Tags: Open access, Epidemiology Source Type: research

Carbohydrate antigen 125 in atrial fibrillation
This article reviews the role of CA-125 in patients with atrial fibrillation.PMID:37683718 | DOI:10.1016/j.cca.2023.117550
Source: International Journal of Clinical Chemistry - September 8, 2023 Category: Chemistry Authors: Rangrang Zhang Weidong Jin Minglei Han Yonglan Hou Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news